Wenhua Zheng obtained his Medical degree and MSc degree in pharmacology from Zhongshan(Sun Yat-sen) University of Medical Science, Guangzhou China, and a Ph.D. degree from the Department of Pharmacology at McGill University, Montreal, Canada. He was awarded several postdoctoral research training positions in prestigious research institutes and universities around the world (Visiting Fellow the NIH 19931996, a Visiting Scientist at the University of Rochester, NY, in 1992, and a PostDoctoral Fellow at McGill University in 1996). He joined as a Professor atSun Yat-sen University in 2006. In 2015, he joined the Faculty of Health Science at the University of Macau. He has a keen interest in cancer, mechanism of cancer metastasis, neuropharmacology; degenerative retinal diseases, molecular mechanisms of neuronal death and survival, and new drug developments in cancer and neurodegenerative disease. Some of the specific current research projects going on in his lab are the alteration of signaling pathways (new biomarkers) in cancer, aging, and degenerative disorders, such as Alzheimer's disease and degenerative retinal diseases, and identification of new biomarkers.
Wenhua Zheng obtained his Medical degree and MSc degree in pharmacology from Zhongshan(Sun Yat-sen) University of Medical Science, Guangzhou China, and a Ph.D. degree from the Department of Pharmacology at McGill University, Montreal, Canada. He was awarded several postdoctoral research training positions in prestigious research institutes and universities around the world (Visiting Fellow the NIH 19931996, a Visiting Scientist at the University of Rochester, NY, in 1992, and a PostDoctoral Fellow at McGill University in 1996). He joined as a Professor atSun Yat-sen University in 2006. In 2015, he joined the Faculty of Health Science at the University of Macau. He has a keen interest in cancer, mechanism of cancer metastasis, neuropharmacology; degenerative retinal diseases, molecular mechanisms of neuronal death and survival, and new drug developments in cancer and neurodegenerative disease. Some of the specific current research projects going on in his lab are the alteration of signaling pathways (new biomarkers) in cancer, aging, and degenerative disorders, such as Alzheimer's disease and degenerative retinal diseases, and identification of new biomarkers.